Beyond Air Appeals Nasdaq Notice on Listing Compliance

Beyond Air ( (XAIR) ) has issued an announcement.

On April 10, 2026, Beyond Air, Inc. disclosed that it had received a notice from Nasdaq staff stating the company was not in compliance with the $1.00 minimum bid price requirement for continued listing, putting its common stock at risk of delisting. On April 13, 2026, the company requested a hearing before a Nasdaq Hearings Panel, which is scheduled for May 14, 2026, and this timely appeal stays any suspension or delisting action while creating uncertainty for shareholders, as there is no assurance the company will secure continued listing or regain compliance within any granted period.

The most recent analyst rating on (XAIR) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Spark’s Take on XAIR Stock

According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and a weakened equity cushion alongside higher debt) and a broader downtrend in technicals (below key longer-term moving averages with negative MACD). Offsetting these is a more constructive earnings-call picture with strong revenue growth, improved gross profit, and reduced quarterly cash burn, but corporate-event risk is elevated due to the Nasdaq delisting notice.

To see Spark’s full report on XAIR stock, click here.

More about Beyond Air

Beyond Air, Inc. is a healthcare company listed on the Nasdaq Stock Market. The company’s common stock is subject to Nasdaq’s continued listing requirements, including maintaining a minimum bid price under Nasdaq Listing Rule 5550(a)(2).

Average Trading Volume: 471,984

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.63M

For detailed information about XAIR stock, go to TipRanks’ Stock Analysis page.